The role of α-Synuclein in neurodegenerative diseases

From molecular pathways in disease to therapeutic approaches

Karima M. Al-Mansoori, Mohamed Y. Hasan, Abdulmonem Al-Hayani, Omar Ali El-Agnaf

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Parkinson disease (PD) is the second most prevalent neurodegenerative disorder after Alzheimer's disease (AD). The formation of the cytoplasmic inclusions named "Lewy bodies" in the brain, considered to be a marker for neuronal degeneration in PD and dementia with Lewy bodies. However, Lewy bodies (LBs) are also observed in approximately 60 percent of both sporadic and familial cases with AD. LBs consist of fibrils mainly formed by post-translational modified α-synuclein (α-syn) protein. The modifications can be truncation, phosphorylation, nitration and mono-, di-, or tri-ubiquitination. Development of disease seems to be linked to events that increase the concentration of α-syn or cause its chemical modification, either of which can accelerate α-syn aggregation. Examples of such events include increased copy number of genes, decreased rate of degradation via the proteasome or other proteases, or modified forms of α-syn. As the aggregation of α-syn in the brain has been strongly implicated as a critical step in the development of several neurodegenerative diseases, the current search for disease-modifying drugs is focused on modification of the process of α-syn deposition in the brain. Recently researchers have screened and designed various molecules that are selectively focused on inhibiting or preventing α-syn aggregation and toxicity. Another strategy that has emerged is to target α-syn expression as a potential therapy for neurodegenerative diseases associated with LBs.

Original languageEnglish
Pages (from-to)559-568
Number of pages10
JournalCurrent Alzheimer Research
Volume10
Issue number6
DOIs
Publication statusPublished - 2013
Externally publishedYes

Fingerprint

Synucleins
Lewy Bodies
Neurodegenerative Diseases
Parkinson Disease
Alzheimer Disease
Brain
Lewy Body Disease
Gene Dosage
Ubiquitination
Inclusion Bodies
Proteasome Endopeptidase Complex
Therapeutics
Peptide Hydrolases
Phosphorylation
Research Personnel
Pharmaceutical Preparations
Proteins

Keywords

  • Alpha-synuclein
  • Alzheimer's disease
  • Dementia with lewy bodies and protein aggregation
  • Drug discovery
  • Lewy bodies
  • Neurodegeneration
  • Parkinson's disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

The role of α-Synuclein in neurodegenerative diseases : From molecular pathways in disease to therapeutic approaches. / Al-Mansoori, Karima M.; Hasan, Mohamed Y.; Al-Hayani, Abdulmonem; Ali El-Agnaf, Omar.

In: Current Alzheimer Research, Vol. 10, No. 6, 2013, p. 559-568.

Research output: Contribution to journalArticle

Al-Mansoori, Karima M. ; Hasan, Mohamed Y. ; Al-Hayani, Abdulmonem ; Ali El-Agnaf, Omar. / The role of α-Synuclein in neurodegenerative diseases : From molecular pathways in disease to therapeutic approaches. In: Current Alzheimer Research. 2013 ; Vol. 10, No. 6. pp. 559-568.
@article{7959aba165924ee0a05a9504c353cb57,
title = "The role of α-Synuclein in neurodegenerative diseases: From molecular pathways in disease to therapeutic approaches",
abstract = "Parkinson disease (PD) is the second most prevalent neurodegenerative disorder after Alzheimer's disease (AD). The formation of the cytoplasmic inclusions named {"}Lewy bodies{"} in the brain, considered to be a marker for neuronal degeneration in PD and dementia with Lewy bodies. However, Lewy bodies (LBs) are also observed in approximately 60 percent of both sporadic and familial cases with AD. LBs consist of fibrils mainly formed by post-translational modified α-synuclein (α-syn) protein. The modifications can be truncation, phosphorylation, nitration and mono-, di-, or tri-ubiquitination. Development of disease seems to be linked to events that increase the concentration of α-syn or cause its chemical modification, either of which can accelerate α-syn aggregation. Examples of such events include increased copy number of genes, decreased rate of degradation via the proteasome or other proteases, or modified forms of α-syn. As the aggregation of α-syn in the brain has been strongly implicated as a critical step in the development of several neurodegenerative diseases, the current search for disease-modifying drugs is focused on modification of the process of α-syn deposition in the brain. Recently researchers have screened and designed various molecules that are selectively focused on inhibiting or preventing α-syn aggregation and toxicity. Another strategy that has emerged is to target α-syn expression as a potential therapy for neurodegenerative diseases associated with LBs.",
keywords = "Alpha-synuclein, Alzheimer's disease, Dementia with lewy bodies and protein aggregation, Drug discovery, Lewy bodies, Neurodegeneration, Parkinson's disease",
author = "Al-Mansoori, {Karima M.} and Hasan, {Mohamed Y.} and Abdulmonem Al-Hayani and {Ali El-Agnaf}, Omar",
year = "2013",
doi = "10.2174/1567205011310060002",
language = "English",
volume = "10",
pages = "559--568",
journal = "Current Alzheimer Research",
issn = "1567-2050",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - The role of α-Synuclein in neurodegenerative diseases

T2 - From molecular pathways in disease to therapeutic approaches

AU - Al-Mansoori, Karima M.

AU - Hasan, Mohamed Y.

AU - Al-Hayani, Abdulmonem

AU - Ali El-Agnaf, Omar

PY - 2013

Y1 - 2013

N2 - Parkinson disease (PD) is the second most prevalent neurodegenerative disorder after Alzheimer's disease (AD). The formation of the cytoplasmic inclusions named "Lewy bodies" in the brain, considered to be a marker for neuronal degeneration in PD and dementia with Lewy bodies. However, Lewy bodies (LBs) are also observed in approximately 60 percent of both sporadic and familial cases with AD. LBs consist of fibrils mainly formed by post-translational modified α-synuclein (α-syn) protein. The modifications can be truncation, phosphorylation, nitration and mono-, di-, or tri-ubiquitination. Development of disease seems to be linked to events that increase the concentration of α-syn or cause its chemical modification, either of which can accelerate α-syn aggregation. Examples of such events include increased copy number of genes, decreased rate of degradation via the proteasome or other proteases, or modified forms of α-syn. As the aggregation of α-syn in the brain has been strongly implicated as a critical step in the development of several neurodegenerative diseases, the current search for disease-modifying drugs is focused on modification of the process of α-syn deposition in the brain. Recently researchers have screened and designed various molecules that are selectively focused on inhibiting or preventing α-syn aggregation and toxicity. Another strategy that has emerged is to target α-syn expression as a potential therapy for neurodegenerative diseases associated with LBs.

AB - Parkinson disease (PD) is the second most prevalent neurodegenerative disorder after Alzheimer's disease (AD). The formation of the cytoplasmic inclusions named "Lewy bodies" in the brain, considered to be a marker for neuronal degeneration in PD and dementia with Lewy bodies. However, Lewy bodies (LBs) are also observed in approximately 60 percent of both sporadic and familial cases with AD. LBs consist of fibrils mainly formed by post-translational modified α-synuclein (α-syn) protein. The modifications can be truncation, phosphorylation, nitration and mono-, di-, or tri-ubiquitination. Development of disease seems to be linked to events that increase the concentration of α-syn or cause its chemical modification, either of which can accelerate α-syn aggregation. Examples of such events include increased copy number of genes, decreased rate of degradation via the proteasome or other proteases, or modified forms of α-syn. As the aggregation of α-syn in the brain has been strongly implicated as a critical step in the development of several neurodegenerative diseases, the current search for disease-modifying drugs is focused on modification of the process of α-syn deposition in the brain. Recently researchers have screened and designed various molecules that are selectively focused on inhibiting or preventing α-syn aggregation and toxicity. Another strategy that has emerged is to target α-syn expression as a potential therapy for neurodegenerative diseases associated with LBs.

KW - Alpha-synuclein

KW - Alzheimer's disease

KW - Dementia with lewy bodies and protein aggregation

KW - Drug discovery

KW - Lewy bodies

KW - Neurodegeneration

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84882738891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882738891&partnerID=8YFLogxK

U2 - 10.2174/1567205011310060002

DO - 10.2174/1567205011310060002

M3 - Article

VL - 10

SP - 559

EP - 568

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

IS - 6

ER -